Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors.
D002648:Child; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005354:Fibrosarcoma / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D008223:Lymphoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D012075:Remission, Spontaneous; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013997:Time Factors; D009396:Wilms Tumor / Q000188:drug therapy
D004317:Doxorubicin; D003630:Daunorubicin